Objective To explore the effect of Dabigatran Etexilate in the treatment of patients with coronary heart disease（CHD） combined with atrial fibrillation undergoing percutaneous coronary intervention（PCI） and its influence on coagulation function and hemorheological indexes. Methods From June 2018 to August 2020 in our department

107 patients with CHD and atrial fibrillation who underwent PCI were selected as the research objects.The control group 53 patients were treated with aspirin and clopidogrel after operation

and 54 patients in the observation group were based on the above treatment. Add dabigatran etexilate capsules to observe the clinical efficacy

coagulation function

hemorheology indexes

bleeding events and thromboembolic events of the two groups of patients. Results After treatment

the total effective rate of the control group was lower than that of the observation group（p<0.05）; the coagulation function was lower than that of the observation group（p<0.05）; the hemorheology indexes were higher than those of the observation group（p<0.05）; bleeding and thrombosis The embolism event was higher than the observation group（p<0.05）. Conclusions Dabigatran Etexilate applied to patients after PCI can effectively improve blood coagulation function

restore hemorheology

improve clinical efficacy

and has high safety.